ABSTRACT
Aim To investigate the effeot of Shenqi Fuzheng injection on the prevention of immune myocarditis induced by anti-PD-1 antibody by reducing the production of inflammatory factors and the expression of myocardial injury markers. Methods Thirty-two maie PD-1 humanized mice with C57BL/6 genetic background were randomly divided into control group, myocarditis model group, anti-PD-1 antibody group and Shenqi Fuzheng injection group (n = 8). Except the control group, mice in other groups were intraperitoneally injected with myocardial myosin heavy chain peptide (5 mg • kg
ABSTRACT
OBJECTIVE@#To evaluate to the efficacy and safety of Shenqi Fuzheng Injection (, SFI) combined with chemotherapy in the treatment of acute leukemia (AL) by meta-analysis.@*METHODS@#PubMed, Cochrane library, Embase, SinoMed, China National Knowledge Infrastructure (CNKI), VIP Journal Integration Platform, Wanfang Database were searched from establishment to November 1, 2018. The randomized controlled trials (RCTs) of SFI combined with chemotherapy in the treatment of AL were included. The Cochrane risk assessment form (RevMan 5.1) was used to evaluate the quality of included studies.@*RESULTS@#A total of 14 RCTs and 1,088 patients was included. The quality evaluation were mostly low risk or unclear. Meta-analysis showed that compared with chemotherapy alone, SFI combined with chemotherapy can improve the total clinical effective rate in patients with AL (RR=1.15, 95% CI: 1.056-1.177; P=0.0001), and relieve adverse reactions caused by chemotherapy drugs, including infection (RR=0.561, 95% CI: 0.397-0.792; P=0.001), nausea and vomiting (RR=0.662, 95% CI: 0.524-0.835; P=0.001), bleeding (RR=0.548, 95% CI: 0.39-0.768; P=0.0001), cardiotoxicity (RR=0.230, 95% CI: 0.080-0.660; P=0.006) and hyperhidrosis (RR=0.348, 95% CI: 0.208-0.581; P=0.0001). The incidence rates of adverse reactions in SFI combined with chemotherapy group were significantly lower than that of the chemotherapy alone group (P<0.01).@*CONCLUSIONS@#Shenqi Fuzheng Injection combined with chemotherapy has good efficacy and safety for AL, and it can alleviate the adverse reactions caused by chemotherapy. However, subject to the limitations of the methodological quality of the literature, the conclusions of this study need to be further verified by large-scale and multi-center RCTs.
Subject(s)
Humans , Drugs, Chinese Herbal/adverse effects , Injections , Leukemia/drug therapy , Treatment OutcomeABSTRACT
AIM: To investigate the effect of Shenqi fuzheng injection (SFI) on tumor immunity and its preliminary molecular mechanism. METHODS: The animal model of low glucose tumor microenvironment was established by B16-PKM2-OE; the level of interleukin-2(IL-2) and interferon-γ(IFN-γ), CD40L and transforming growth factor-β1(TGF-β1) were detected by ELISA kit; the expressions of glucose transporter-1 (Glut-1) and key enzymes of glycolysis ( HK, PFK and PK ) in CD4
ABSTRACT
Objective::To investigate the effect of Shenqi Fuzheng injection on the sensitivity of cisplatin through immunomodulation, in order to explore its mechanisms. Method::The cell survival was measured by thiazolyl blue tetrazolium bromide (MTT), the rate of apoptosis was detected by flow cytometry, the expressions of apoptosis-related proteins were detected by Western blot, and the expression level of cytokines was detected by enzyme linked immunosorbent assay (ELISA). Result::Shenqi Fuzheng injection 1, 10, 100 mL·L-1 significantly inhibited the growth of co-cultured cells, and the cell survival rate was 71.8%and 59.9%at the concentration of 10, 100 mL·L-1 respectively.Shenqi Fuzheng injection 10 mL·L-1 combined with cisplatin significantly increased the sensitivity of co-cultured cells to cisplatin.The half maximal inhibitory concentration (IC50) of cisplatin was reduced from 30 to 15 μmol·L-1.The rate of apoptosis induced by the combined treatment increased by 15.5%compared with that of cisplatin 15 μmol·L-1 (P<0.05). The expressions of B-cell lymphoma-2 (Bcl-2), B-cell lymphoma-w (Bcl-w) and B-cell lymphoma-extra large (Bcl-xl) were inhibited, and the expressions of Bcl-2-associated X protein (Bax) and protein induced by BH3 domain (Bid) apoptosis were increased (P<0.05). Shenqi Fuzheng injection reduced the release of interleukin-10 (IL-10) and prostaglandin E2 (PGE2) induced by cisplatin (P<0.05). Conclusion::Shenqi Fuzheng injection improves the sensitivity of MDA-MB-231 to cisplatin by regulating immune cells, and plays a synergistic role in inhibiting the proliferation of breast cancer cells.This study provides experimental basis for the prevention and treatment of tumors with Yiqi Fuzheng method, and experimental reference for the study of traditional Chinese medicine in alleviating drug resistance of tumors.
ABSTRACT
Objective: To study the changes of mitochondria function and dynamics in colon cancer-cachexia mice and the effects of Shenqi Fuzheng Injection on these changes. Methods: A total of 40 female BLAB/c nu mice were randomly divided into control group, model group, low dose and high does of Shenqi Fuzheng Injection group, ten mice in every group. Except the control group, the mice of other groups were intraperitoneal injected with the Lovo cell line to establish the model of abdominal metastasis of colon cancer, then induced cancer cachexia. Marasmus and weight change were monitored the status of cancer cachexia in all groups. Shenqi Fuzheng Injection groups received intraperitoneal injection with 1.5 mL (2 times dose) and 3 mL (4 times dose) of drugs for every three days, seven consecutive times. After 21 days treatment, the mitochondrial related protein PGC-1, 4HNE and VDAC1 in the skeletal muscle were measured. The levels of adenosine triphosphate (ATP) and malondialdehyde (MDA) in the skeletal were detected. Results: Compared to the control group, the mice in the model group and Shenqi Fuzheng group suffered from cancer cachexia. Compared with the control group, the level of ATP in the skeletal muscle was lower in model group; The protein expression level of PGC-1 and 4HNE were remarkably increased (P 0.05); The level of MDA was significantly increased (P 0.05); The level of MDA was lower (P < 0.05). Conclusion: Shenqi Fuzheng Injection can significantly improve the status of colon cancer cachexia in mice, which may be related to the improvement of the mitochondrial function and the relieving of the mitochondrial oxidative damage.
ABSTRACT
OBJECTIVE： To systematically evaluate the effects of Shenqi fuzheng injection combined with conventional chemotherapy on the immune function of patients with advanced non-small cell lung cancer （NSCLC）， and provide evidence-based reference for clinical medication. METHODS： Retrieved from Cochrane Library， PubMed， Medline， Embase， CNKI， Wanfang database， VIP and CBM， Shenqi fuzheng injection combined with conventional chemotherapy （trial group） versus conventional therapy （control group） for advanced NSCLC were collected. After literature screening， data extraction and quality evaluation with Cochrane system evaluator manual 5.1.0 risk evaluation tool， Meta-analysis was performed by using Rev Man 5.3 statistical software. RESULTS： A total of 16 literatures were included， involving 1 324 cases. Results of Meta-analysis showed that there were no statistical significance in the difference of objective remission rate （ORR） [RR＝1.14， 95％CI（0.91，1.43）， P＝0.25] and the level of CD8+ [MD＝－1.26，95％CI（－4.10， 1.59），P＝0.39] between 2 groups. The levels of CD3+ [MD＝17.48， 95％CI（13.40， 21.56）， P＜0.000 01 ]， CD4+[MD＝12.26， 95％CI（8.39 16.13）， P＜0.000 01]， CD4+/CD8+ [MD＝0.33，95％CI（0.27， 0.39），P＜0.000 01] and the percentage of NK cells [MD＝9.33， 95％CI（5.72， 12.94）， P＜0.000 01] in trial group were significantly higher than control group. Results of subgroup analysis for medication duration of Shenqi fuzheng injection showed that after 1-14 d treatment of Shenqi fuzheng injection， the levels of CD3+ [MD＝17.11， 95％CI（12.37 ，23.17），P＜0.000 01]， CD4+[MD＝13.28，95％CI（8.33， 18.23），P＜0.000 01]， CD4+/CD8+[MD＝0.36，95％CI（0.28，0.43），P＜0.000 01] and the percentage of NK cells [MD＝12.06，95％CI（7.52，16.61），P＜0.000 1] in trial group were significantly higher than control group. After 21 d treatment of Shenqi fuzheng injection， the levels of CD3+[MD＝14.88， 95％CI（7.51，22.26），P＜0.000 01]， CD4+[MD＝10.56，95％CI（5.57，15.56），P＜0.000 01]， CD8+[MD＝3.02， 95％CI（1.80， 4.23），P＜0.000 01]， CD4+/CD8+[MD＝0.29，95％CI（0.23， 0.35），P＜0.000 01] and the percentage of NK cells [MD＝5.58，95％CI（2.49， 8.67），P＝0.000 4] in trial group were significantly higher than control group. There was no statistical significance in the level of CD8+ between 2 groups after 7-14 d treatment of Shenqi fuzheng injection [MD＝－4.26，95％CI（－12.60， 4.09），P＝0.32]. The incidence of leukopenia， nausea and vomiting， and renal dysfunction in trial group were significantly lower than control group. There was no statistical significance in the incidence of hemoglobin decreased and thrombocytopenia between 2 groups. The results of publication bias showed that there was a greater possibility of publication bias in this study. CONCLUSIONS： Shenqi fuzheng injection combined with conventional chemotherapy may improve the immune function of patients with advanced NSCLC and improve the safety after chemotherapy. But more large-scale， milltiple-center and high-quality RCT are needed to validate this conclusion.
ABSTRACT
Databases including China Biological Medicine database(CBM), Chinese scientific journals full-text database(VIP), China National Knowledge Infrastructure database(CNKI), WanFang Data, PubMed, and EMbase were searched from inception to March 2018 to collect the randomized controlled trials(RCTs) on Shenqi Fuzheng Injection combined with chemotherapy for the treatment of breast cancer. All included studies were critically appraised by two independent reviewers by following the cochrane systematic review method and using Revman 5.3 software and State 12.0 for data analysis. After screening, 20 RCTs involving 2 095 patients were included in the study. Meta-analysis showed that as compared with control group of chemotherapy alone, Shenqi Fuzheng Injection combined with chemotherapy could improve the clinical curative efficiency, the KPS score, and immune function indexes such as total T cells, Th cells and Ts cells; inhibit the decline of white blood cells(WBC), platelets in blood system, T-lymphocyte subsets such as CD3~+, CD4~+, CD4~+/CD8~+, alleviate myelosuppression and reduce the incidence of side effects such as gastrointestinal adverse reaction, liver and kidney dysfunction and abnormal electrocardiogram. The results revealed that for clinical breast cancer patients, Shenqi Fuzheng Injection combined with chemotherapy could significantly improve its clinical efficacy and reduce adverse reactions. However, the conclusions still need to be verified by high-quality, multi-center, large-sample, prospective, randomized and double-blind clinical trials. In conclusion, this study has systemically evaluated the efficacy and safety of Shenqi Fuzheng Injection combined with chemotherapy in treatment of breast cancer and provided the reference of evidence-based medicine for safe and effective clinical application of medicines.
Subject(s)
Female , Humans , Antineoplastic Agents , Therapeutic Uses , Breast Neoplasms , Drug Therapy , China , Drugs, Chinese Herbal , Therapeutic Uses , Randomized Controlled Trials as Topic , T-Lymphocyte SubsetsABSTRACT
OBJECTIVE:To evaluate the clinical efficacy and safety of Shenqi fuzheng injection combined with chemotherapy in the treatment of colorectal cancer.METHODS:Retrieved from PubMed,EMBase,Clinical Trials,Cochrane Library,CJFD,CBM,Wanfang database and VIP,RCTs about Shenqi fuzheng injection combined with chemotherapy (trial group) vs.chemotherapy alone (control group) in the treatment of colorectal cancer were included.Meta-analysis was performed by Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane system evaluator manual.RESULTS:A total of 25 RCTs were included,involving 1 987 patients.Results of Meta-analysis showed that objective remission rate of trial group was significantly higher than control group [RR=1.19,95％ CI (1.02,1.39),P=0.02];the improvement of survival quality was significantly better than control group [RR=1.72,95％CI(1.49,1.99),P＜0.001];CD4VCD8+ was significantly higher than control group [MD=0.40,95％ CI (0.29,0.50),P＜0.001];the incidence of gastrointestinal reaction was significantly higher than control group [RR=0.59,95％CI(0.52,0.68),P＜0.001];the incidence of liver and renal injury was significantly lower than control group [RR=0.52,95％CI(0.41,0.67),P＜0.001],with statistical significance.CONCLUSIONS:Shenqi fuzheng injection combined with chemotherapy can improve objective remission rate of colorectal cancer patients,survival quality and immune function,and reduce the occurrence of toxic reation.
ABSTRACT
Objective To observe the effect of Shenqi Fuzheng injection combined with chemotherapy on reducing the side effects of malignant tumor chemotherapy. Methods Eighty cancer patients in Traditional Chinese Medicine Hospital of PLA General Hospital from January 2015 to March 2017 were randomly divided into treatment group and control group by using random number table method, each group contained 40 cases. The patients in the treatment group were given Shenqi Fuzheng injection combined with chemotherapy, while the control group used chemotherapy only. Results The incidence of WBC and Plt reduction in the treatment group [35.0 % (14/40), 32.5 % (13/40)] was lower than those in the control group [70.0 % (28/40), 57.5 % (23/40)], and the differences were statistically significant (χ 2= 9.825, P = 0.002;χ2=5.051, P=0.025). The incidence rates of digestive tract reaction and oral ulcers[52.5 %(21/40), 32.5 % (13/40)]were lower than those in the control group[75.0 %(30/40), 60.0 %(24/40)], and the differences were statistically significant (χ2= 4.381, P = 0.036; χ2= 6.084, P = 0.014). The quality of life in the treatment group was significantly improved compared with the control group [(51.4 ±5.1) points vs. (48.3±5.5) points], and the difference was statistically significant(t =2.595,P =0.011). Conclusions Shenqi Fuzheng injection combined with chemotherapy can reduce chemotherapy-induced side effects and improve the life quality of the patients.The injection can be used as the adjuvant therapy for chemotherapy in clinic application.
ABSTRACT
Objective To study the effect of Shenqi Fuzheng injection on proliferation of gastric cancer cell line SGC7901, and to explore its mechanism associated with the STAT3 pathway. Methods The human gastric cancer cell line SGC7901 was used as the research object, the effects of different concentrations of Shenqi Fuzheng injection on the activity of SGC7901 cells were observed by MTT method, the levels of interleukin(IL)-6,IL-8 and IL-11 were detected by enzyme-linked immunosorbent assay(ELISA), and the expressions of Janus kinase 2(JAK2), STAT3 and phosphorylated-STAT3(p-STAT3) were detected by Western blot. Results Compared with the control group,the activity of SGC7901 cells in the treatment group decreased significantly, and the concentration of Shenqi Fuzheng injection reached 0.1 mg/ml, the inhibitory rate of SGC7901 cells reached (10.8±0.7) %, and the difference was statistically significant (P< 0.01). With the increase of Shenqi Fuzheng injection concentration, the inhibition rate of SGC7901 cells increased gradually (F =12.319, P =0.000). Compared with the control group, with the increase of Shenqi Fuzheng injection concentration, IL-6, IL-8 and IL-11 contents were decreased in SGC7901 cells, the differences were statistically significant (IL-6: F = 31.256, P = 0.000; IL-8: F = 16.857, P = 0.000; IL-11: F = 21.319, P =0.000);JAK2 and p-STAT3 protein levels were significantly reduced(JAK2:F =12.315,P =0.000;p-STAT3:F= 16.728, P= 0.000) in the treatment groups. Conclusion Shenqi Fuzheng injection can inhibit the proliferation of SGC7901 cells,and the mechanism may be related to the inhibition of STAT3 pathway.
ABSTRACT
Objective:To investigate the inhibitory effect of Shenqi Fuzheng injection on the expression of VEGF gene in human hepatocellular carcinoma cell line MHCC97L,and to elucidate the effect of Shenqi Fuzheng injection on tumor invasiveness,and to validate it through siRNA technology.Methods:After 24 hours of addition of Shenqi Fuzheng Injection (MHC) in the culture system of MHCC97L,Real-time PCR and Western-blot were used to detect the expression of MMP-9 and MMP-9 in the control group (Shenqi Fuzheng),negative control group (NaCI) And the expression of VEGF and RNA in the blank control group,and to determine the effect of Shenqi Fuzheng injection on the expression of VEGF and RNA.The effect of Shenqi Fuzheng Injection on the invasiveness of MHCC97L cells was detected by Transwell assay.The lentiviral vectors of MHCC97L cells were transfected into 293T cells and transfected into MHCC97L cells.The transfected cells were transfected into 293T cells by Lipofectamine 2000,and transfected into MHCC97L cells.The Effect of Shenqi Fuzheng Injection on the Invasion of VEGFi Tumor by Transwell.Results:Shenqi Fuzheng injection could significantly decrease the expression of VEGF mRNA and protein in normal MHCC97L cells (P＜0.05),and decrease the invasiveness of tumor cells (P＜0.05).VEGF RNA interference was successful.After intervention,Shenqi Fuzheng injection could not decrease the invasiveness of MHCC97L tumor (P＞0.05).Conclusion:Shenqi Fuzheng injection can reduce the invasion of MHCC97L cells by inhibiting the expression of VEGF gene.
ABSTRACT
OBJECTIVE:To evaluate the effectiveness and safety of Shenqi fuzheng injection assisting TACE in the adjuvant treatment of primary liver carcinoma,and to provide evidence-based reference.METHODS:Retrieved from CJFD,Wanfang database,VIP and PubMed,randomized controlled trials (RCTs) about Shenqi fuzheng injection assisting TACE (trial group) vs.TACE alone (control group) in the treatment of primary liver carcinoma were collected.Meta-analysis was performed by using Stata 12.0 software after data extraction and quality evaluation according to improved Jadad scale.RESULTS:A total of 8 RCTs were included,involving 527 patients.Results of Meta-analysis showed that there was no statistical significance in response rate [RR=1.19,95％CI(0.97,1.46),P=0.091] and clinical benefit rate [RR=1.16,95％CI(0.90,1.48),P=0.251] of 2 groups.The rate of life quality improvement in trial group was significantly higher than control group [RR=2.26,95 ％ CI (1.64,3.10),P=0.001],while the incidence of above middle fever [RR=0.74,95％ CI (0.63,0.88),P=0.001],gastrointestinal reaction [RR=0.52,95％ CI (0.32,0.85),P=0.010] and leucocyte reduction rate [RR=0.75,95％ CI (0.62,0.92),P=0.005],were significantly lower than control group,with statistical significance.CONCLUSIONS:Shenqi fuzheng injection assisting TACE for primary liver carcinoma cannot improve therapeutic efficacy but improve the quality of life and reduce the incidence of gastrointestinal reaction and leucocyte reduction.
ABSTRACT
OBJECTIVE:To evaluate the effectiveness and safety of Shenqi fuzheng injection assisting TACE in the adjuvant treatment of primary liver carcinoma,and to provide evidence-based reference.METHODS:Retrieved from CJFD,Wanfang database,VIP and PubMed,randomized controlled trials (RCTs) about Shenqi fuzheng injection assisting TACE (trial group) vs.TACE alone (control group) in the treatment of primary liver carcinoma were collected.Meta-analysis was performed by using Stata 12.0 software after data extraction and quality evaluation according to improved Jadad scale.RESULTS:A total of 8 RCTs were included,involving 527 patients.Results of Meta-analysis showed that there was no statistical significance in response rate [RR=1.19,95％CI(0.97,1.46),P=0.091] and clinical benefit rate [RR=1.16,95％CI(0.90,1.48),P=0.251] of 2 groups.The rate of life quality improvement in trial group was significantly higher than control group [RR=2.26,95 ％ CI (1.64,3.10),P=0.001],while the incidence of above middle fever [RR=0.74,95％ CI (0.63,0.88),P=0.001],gastrointestinal reaction [RR=0.52,95％ CI (0.32,0.85),P=0.010] and leucocyte reduction rate [RR=0.75,95％ CI (0.62,0.92),P=0.005],were significantly lower than control group,with statistical significance.CONCLUSIONS:Shenqi fuzheng injection assisting TACE for primary liver carcinoma cannot improve therapeutic efficacy but improve the quality of life and reduce the incidence of gastrointestinal reaction and leucocyte reduction.
ABSTRACT
Objective:To investigate the inhibitory effect of Shenqi Fuzheng injection on the expression of VEGF gene in human hepatocellular carcinoma cell line MHCC97L,and to elucidate the effect of Shenqi Fuzheng injection on tumor invasiveness,and to validate it through siRNA technology.Methods:After 24 hours of addition of Shenqi Fuzheng Injection (MHC) in the culture system of MHCC97L,Real-time PCR and Western-blot were used to detect the expression of MMP-9 and MMP-9 in the control group (Shenqi Fuzheng),negative control group (NaCI) And the expression of VEGF and RNA in the blank control group,and to determine the effect of Shenqi Fuzheng injection on the expression of VEGF and RNA.The effect of Shenqi Fuzheng Injection on the invasiveness of MHCC97L cells was detected by Transwell assay.The lentiviral vectors of MHCC97L cells were transfected into 293T cells and transfected into MHCC97L cells.The transfected cells were transfected into 293T cells by Lipofectamine 2000,and transfected into MHCC97L cells.The Effect of Shenqi Fuzheng Injection on the Invasion of VEGFi Tumor by Transwell.Results:Shenqi Fuzheng injection could significantly decrease the expression of VEGF mRNA and protein in normal MHCC97L cells (P＜0.05),and decrease the invasiveness of tumor cells (P＜0.05).VEGF RNA interference was successful.After intervention,Shenqi Fuzheng injection could not decrease the invasiveness of MHCC97L tumor (P＞0.05).Conclusion:Shenqi Fuzheng injection can reduce the invasion of MHCC97L cells by inhibiting the expression of VEGF gene.
ABSTRACT
Objective To investigate the clinical efficacy of Shenqi Fuzheng injection and chemotherapy in elderly patients with non-small cell lung cancer(NSCLC),and to observe its effect on immune function and serum tumor markers of carcino embryonie antigen(CEA),carbohydrate antigen 19-9(CA19-9),cytokeratin 19 fragment(CYFRA21-1)and neuronspecific enolase(NSE).Methods 80 patients with NSCLC who were confirmed as non-small cell lung cancer were enrolled in the study.Among them,the control group received paclitaxel + carboplatin chemotherapy,40 patients; the treatment group received Shenqi Fuzheng injection on the basis of the control group,40 cases.The clinical curative effect was evaluated after four cycles of treatment and the adverse reactions were recorded.The scores of traditional Chinese medicine(TCM)syndrome before and after four cycles of treatment were evaluated,and the quality of life of the patients before and after treatment were evaluated by Karnofsky performance score(KPS).The immune function and tumor markers were measured before and after treatment.Results The total effective rate of the treatment group was 65.0％,which was significantly higher than that of the control group(42.5％,χ2=4.07,P=0.04).In the treatment group,the adverse reaction rate was 37.5％,significantly lower than 62.5％in the control group(χ2=5.00,P=0.02).The score of TCM syndrome in the two groups was significantly lower than that in the control group before treatment,and the KPS score was significantly higher than that in the control group before treatment,the score of TCM syndrome in the treatment group was significantly lower than that in the control group(P<0.05).After treatment,the immune function of patients in the treatment group compared with before treatment had no significant difference,while the control group after treatment of the immune function was significantly lower than before treatment,and compared with the treatment group(P<0.05).The two groups of patients after treatment of tumor markers decreased significantly,and the treatment group decreased significantly compared with the control group(P<0.05).Conclusion Supplemented with Shenqi Fuzheng injection in the treatment of elderly non-small cell lung cancer on the immune function of little effect,help to promote serum levels of serum tumor markers and clinical symptoms improved,reduce adverse reactions,improve clinical efficacy and quality of life.
ABSTRACT
Objective To study the effect of Shenqi Fuzheng injection on immune function and quality of life in patients with advanced gastric cancer.Methods 100 Patients with advanced gastric cancer treated from July 2014 to April 2017 in our hospital were randomly divided into two groups.The patients in the control group were treated with conventional FOLTOX regimen.The patients in the experimental group received Shenqi Fuzheng injection.The immunological function and quality of life of the two groups were analyzed and analyzed.Results Compared with the control group, the content of CD3+ was significantly improved in the patients treated with Shenqi Fuzheng Injection, the content of CD8+ was effectively decreased and the CD4+ / CD8+ ratio was effectively improved.Shenqi Fuzheng injection can effectively improve the immune function of patients, the difference was statistically significant(P<0.01).The number of patients in the treatment group was 39, and the control group was 26, the difference was statistically significant(x2 =7.43, P<0.01).There were 40 patients with sleep improvement in the treatment group and 25 patients in the control group, the difference was statistically significant(x2 =9.89, P<0.01).Conclusion Applying Shenqi Fuzheng Injection on FOLTOX can effectively improve the immunity of patients and improve the quality of life.Shenqi Fuzheng injection in clinical worthy of promotion.
ABSTRACT
Objective To evaluate the efficacy and safety of Shenqi Fuzheng injection in the treatment of patients with laparoscopic gastric cancer. Methods A total of 94 cases with laparoscopic gastric cancer included in this study were divided into control group and experimental group with 47 cases in each group.The patients in both groups received laparoscopic gastric carcinoma.Patients in control group received fluorouracil, leucovorin and oxaliplatin infusion( FOLFOX4 ) chemotherapy and patients in the experimental group revieved Shenqi Fuzheng injection.Both groups received two courses treatment of 14 days for one course.The clinical efficacy, inflammatory levels, tumor indicators and adverse drug reactions were compared between the two groups.Results The clinical efficacy in experimental group was 95.74%, which was significantly higher than that in control group 82.98%(P<0.05 ) .The serum level of serum serum albumin (ALB), prealbumin (PA), glutathione-S-transferase (GST), carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) after treatment in experimental group were lower than the control group (P<0.05) .The adverse drug reactions was not statistically different between the two groups.Conclusion Shenqi Fuzheng injection has significant efficacy in the treatment of laparoscopic gastric cancer with high safety.
ABSTRACT
Objective To observe the therapeutic effect of Shenqi Fuzheng injection combined with EP chemotherapy in the treatment of non small cell lung cancer (NSCLC),and to improve the quality of life and side effects.Methods 60 cases of NSCLC were randomly divided into observation group and control group,30 cases in each group.The two groups were treated with EP,the observation group was treated with Shenqi Fuzheng injection for two courses.The life quality and adverse effects were observed.Results The quality of life of the two groups after treatment was compared,the difference was statistically significant (93.3% vs 70.0%,χ2 =2.83,P <0.05),the quality of life in the observation group was significantly higher than that in the control group.The white blood cell reduction,anemia and liver and kidney function damage between the two groups had statistically significant differences (P =0.011,0.025,0.016),the adverse reaction of the observation group was less than the control group.Conclusion Shenqi Fuzheng injection combined with EP regimen in the treatment of NSCLC can protect bone marrow hematopoietic function and improve the quality of life of patients with NSCLC chemotherapy.It can be used as one mean of Chinese and western treatment for patients with NSCLC in clinical application.
ABSTRACT
Prospective, multi-center, large-sample and registered design was used to analyze the drug combination features of Shenqi Fuzheng injection in the real world clinical application, and comprehend the drug combination in the real world. A total of 30 026 patients with the use of Shenqi Fuzheng injection were registered, where the chemical drugs were used for 57 436 times (accounting for 82.76%), and the Chinese patent medicines were used for 11 962 times (accounting for 17.24%), mainly including anti-acid drugs and anti-ulcer drugs, nutritional agent, immune enhancement agent, etc. According to the association rules, drug combinations of 2 drugs were closely related to inhibiting gastric acid secretion and anti-tumor; drug combinations of 3 drugs were closely related to inhibiting gastric acid secretion, antiemetic and anti tumor; drug combinations of 4 drugs were closely related to inhibiting gastric acid secretion, antiemetic, anti-tumor, and immune enhancement. The above results were consistent with the Instruction, providing clues for accurate treatment, and laying the foundation for clinical rational drug use.
ABSTRACT
OBJECTIVE:To establish a method for the contents determination of astragalosidesⅠ,Ⅱ,Ⅲ,Ⅳ,lobetyolin and for-mononetin in Shenqi fuzheng injection. METHODS:HPLC was performed. The detector was evaporative light scattering detector, column was Ultimate XB-C18 with mobile phase of acetonitrile-0.5% formic acid (gradient elution) at a flow rate of 1.2 ml/min, column temperature was 30 ℃,and injection volume was 10 μl. RESULTS:The linear range was 0.62-5.67 μg for astragalosidesⅠ(r=0.999 6),0.78-6.31 μg for astragalosidesⅡ(r=0.999 6),0.36-3.48 μg for astragalosidesⅢ(r=0.999 7),0.81-6.72 μg for as-tragalosides Ⅳ(r=0.999 5),0.82-7.03 μg for lobetyolin(r=0.999 8)and 0.58-6.62 μg(r=0.999 7)formononetin;limit of quan-titation was 1.21,0.15,0.12,0.03,0.12,0.17 μg/ml;limit of detection was 0.35,0.35,0.04,0.01,0.03,0.04 μg/ml;RSDs of pre-cision,stability and reproducibility tests were lower than 2%;recoveries were 95.1%-101.1%(RSD=2.0%,n=9),95.2%-100.7%(RSD=1.9%,n=9),95.8%-100.2%(RSD=1.4%,n=9),96.2%-100.6%(RSD=1.7%,n=9),96.6%-101.2%(RSD=1.4%, n=9) and 95.9%-99.5%(RSD=1.2%,n=9),respectively. CONCLUSIONS:The method is simple and accurate,and can be used for the simultaneous determination of astragalosidesⅠ,Ⅱ,Ⅲ,Ⅳ,lobetyolin and formononetin in Shenqi fuzheng injection.